Revance Therapeutics, Inc. provided earnings guidance for the year 2017. For the year, the company anticipates 2017 GAAP research and development expense to be in the range of $75 million to $83 million, which when excluding depreciation of $1 million to $2 million and estimated stock-based compensation of $5 million to $6 million, results in projected 2017 non-GAAP research and development expense of $69 million to $75 million.